Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

465 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply to letter to the editor by Yoshii.
Nagayama Y, Ebina K, Tsuboi H, Hirao M, Hashimoto J, Yoshikawa H, Okada S, Nakata K. Nagayama Y, et al. J Orthop Sci. 2023 May;28(3):717-718. doi: 10.1016/j.jos.2023.02.023. Epub 2023 Mar 10. J Orthop Sci. 2023. PMID: 36907777 No abstract available.
The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
Kaneshiro S, Ebina K, Hirao M, Tsuboi H, Nishikawa M, Nampei A, Nagayama Y, Takahi K, Noguchi T, Owaki H, Hashimoto J, Yoshikawa H. Kaneshiro S, et al. Among authors: nagayama y. Mod Rheumatol. 2017 Jan;27(1):42-49. doi: 10.1080/14397595.2016.1181315. Epub 2016 May 16. Mod Rheumatol. 2017. PMID: 27181115
Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
Ebina K, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, Nakaya H, Kunugiza Y, Hirao M, Okamura G, Etani Y, Takami K, Goshima A, Miura T, Nakata K, Okada S. Ebina K, et al. Among authors: nagayama y. Joint Bone Spine. 2021 Oct;88(5):105219. doi: 10.1016/j.jbspin.2021.105219. Epub 2021 May 19. Joint Bone Spine. 2021. PMID: 34020048
Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
Ebina K, Etani Y, Tsuboi H, Nagayama Y, Kashii M, Miyama A, Kunugiza Y, Hirao M, Okamura G, Noguchi T, Takami K, Goshima A, Miura T, Fukuda Y, Kurihara T, Okada S, Nakata K. Ebina K, et al. Among authors: nagayama y. Osteoporos Int. 2022 Aug;33(8):1807-1813. doi: 10.1007/s00198-022-06386-y. Epub 2022 Apr 1. Osteoporos Int. 2022. PMID: 35362725
Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis.
Ebina K, Etani Y, Tsuboi H, Nagayama Y, Kashii M, Miyama A, Kunugiza Y, Hirao M, Okamura G, Noguchi T, Takami K, Goshima A, Miura T, Fukuda Y, Kurihara T, Okada S, Nakata K. Ebina K, et al. Among authors: nagayama y. Osteoporos Int. 2022 Nov;33(11):2441-2443. doi: 10.1007/s00198-022-06545-1. Epub 2022 Sep 6. Osteoporos Int. 2022. PMID: 36066579 No abstract available.
An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study.
Ebina K, Nagayama Y, Kashii M, Tsuboi H, Okamura G, Miyama A, Etani Y, Noguchi T, Hirao M, Miura T, Fukuda Y, Kurihara T, Nakata K, Okada S. Ebina K, et al. Among authors: nagayama y. Osteoporos Int. 2024 May;35(5):841-849. doi: 10.1007/s00198-024-07019-2. Epub 2024 Jan 31. Osteoporos Int. 2024. PMID: 38296866 Free PMC article.
465 results